Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml

Science Communicator Platform

Share By

Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml Publisher Pubmed

Mahalleh M¹ ; Shabani M^{1, 2, 3} ; Rayzan E^{1, 2} ; Rezaei N^{2, 3, 4}

Source: Immunotherapy Published:2019

Abstract

Recent therapeutic advances in cancer treatment recruit immune system potentiation against malignant cells. Numerous ongoing clinical trials on immunotherapy methods, either monotherapy or combination therapy, are investigating the impeding factors on the way of acute myeloid leukemia (AML) treatment. Due to the genetic diversity in AML progenitors, combining various strategies is more likely to be useful for improving patient outcomes. This review describes the details of applying monoclonal antibodies against AML, focusing on CD33, CD123, FLT3, CD45 and CD66 targeting. Furthermore, it clarifies the importance of immunotoxins, bispecific antibodies, chimeric antigen receptor (CAR)-T cells and T cell receptor-modified cells as reinforcing agents for monoclonal antibodies. © 2019 © 2019 Future Medicine Ltd.

Related Docs

View other Related Docs

1. Immunopathology and Immunotherapy of Myeloid Leukemia, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

2. Exploring Cd19-Targeted Immunotherapy Strategies for Human B-Cell Lymphoma, Archives of Razi Institute (2025)

3. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (3)

Saeid Amanpour (1)

Other Related Docs

4. Exploring Cd19-Targeted Immunotherapy Strategies for Human B-Cell Lymphoma, Archives of Razi Institute (2025)

5. Hematologic Malignancies and an Overview of Emerging Therapies for Hematologic Malignancies: A Systematic Review, Cancer Treatment and Research Communications (2026)

6. Tumor-Associated Macrophages, Nanomedicine and Imaging: The Axis of Success in the Future of Cancer Immunotherapy, Immunotherapy (2017)

7. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)

8. The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer, Current Cancer Drug Targets (2025)

9. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

10. Abscopal Effect in Radioimmunotherapy, International Immunopharmacology (2020)

11. Anti-Ctla-4 Nanobody As a Promising Approach in Cancer Immunotherapy, Cell death & disease (2024)

12. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)

13. Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma, Journal of Cellular Biochemistry (2019)

14. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)

15. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)

16. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)

17. Breast Cancer Immunotherapy: Current and Novel Approaches, International Immunopharmacology (2021)

18. Dendritic Cell Vaccination Strategy for the Treatment of Acute Myeloid Leukemia: A Systematic Review, Cytotherapy (2024)

19. Combination Therapy With Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges, Resistance Mechanisms, and the Role of Microbiota, Biomedicine and Pharmacotherapy (2025)

20. New Approaches in Cancer Immunotherapy: Review Article, Tehran University Medical Journal (2018)

Style	Citing Format
MLA	Mahalleh M, et al.. "Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml." Immunotherapy, vol. 11, no. 18, 2019, pp. 1583-1600.
APA	Mahalleh M, Shabani M, Rayzan E, Rezaei N (2019). Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml. Immunotherapy, 11(18), 1583-1600.
Chicago	Mahalleh M, Shabani M, Rayzan E, Rezaei N. "Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml." Immunotherapy 11, no. 18 (2019): 1583-1600.
Harvard	Mahalleh M et al. (2019) 'Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml', Immunotherapy, 11(18), pp. 1583-1600.
Vancouver	Mahalleh M, Shabani M, Rayzan E, Rezaei N. Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml. Immunotherapy. 2019;11(18):1583-1600.
BibTex	@article{ author = {Mahalleh M and Shabani M and Rayzan E and Rezaei N}, title = {Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml}, journal = {Immunotherapy}, volume = {11}, number = {18}, pages = {1583-1600}, year = {2019} }
RIS	TY - JOUR AU - Mahalleh M AU - Shabani M AU - Rayzan E AU - Rezaei N TI - Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml JO - Immunotherapy VL - 11 IS - 18 SP - 1583 EP - 1600 PY - 2019 ER -

Science Communicator Platform

Authors

Abstract